The potential for allosteric inhibitors to achieve greater selectivity and tolerability due to widened therapeutic window and features of best-in-class TKIs. (A) List of approved orthosteric and allosteric BCR::ABL1 TKIs. Schematic depiction of how allosteric TKIs may achieve improved potency and a widened therapeutic window through more selective target kinase inhibition. (B) Table describing best-in-class features of TKIs.